Identification of a NACC1-Regulated Gene Signature Implicated in the Features of Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC), characterized by a deficiency in estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor2 (HER2), is among the most lethal subtypes of breast cancer (BC). Nevertheless, the molecular determinants that contribute to its malignant phenotypes such as tumor heterogeneity and therapy resistance, remain elusive. In this study, we sought to identify the stemness-associated genes involved in TNBC progression. Using bioinformatics approaches, we found 55 up- and 9 downregulated genes in TNBC. Out of the 55 upregulated genes, a 5 gene-signature (CDK1, EZH2, CCNB1, CCNA2, and AURKA) involved in cell regeneration was positively correlated with the status of tumor hypoxia and clustered with stemness-associated genes, as recognized by Parametric Gene Set Enrichment Analysis (PGSEA). Enhanced infiltration of immunosuppressive cells was also positively correlated with the expression of these five genes. Moreover, our experiments showed that depletion of the transcriptional co-factor nucleus accumbens-associated protein 1 (NAC1), which is highly expressed in TNBC, reduced the expression of these genes. Thus, the five genes signature identified by this study warrants further exploration as a potential new biomarker of TNBC heterogeneity/stemness characterized by high hypoxia, stemness enrichment, and immune-suppressive tumor microenvironment.

[1]  P. Ordóñez-Morán,et al.  Challenges for Triple Negative Breast Cancer Treatment: Defeating Heterogeneity and Cancer Stemness , 2022, Cancers.

[2]  Jingqing Yang,et al.  Expression of NAC1 Restrains the Memory Formation of CD8+ T Cells during Viral Infection , 2022, Viruses.

[3]  Liang Yang,et al.  Hypoxia, a key factor in the immune microenvironment. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[4]  Jingqing Yang,et al.  Tumorous expression of NAC1 restrains antitumor immunity through the LDHA-mediated immune evasion , 2022, Journal for ImmunoTherapy of Cancer.

[5]  M. Di Nicola,et al.  BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer , 2022, Cellular Oncology.

[6]  Jianlong Wang,et al.  NAC1 modulates autoimmunity by suppressing regulatory T cell–mediated tolerance , 2022, bioRxiv.

[7]  Zhaohui S. Qin,et al.  UALCAN: An update to the integrated cancer data analysis platform , 2022, Neoplasia.

[8]  Shannon E. McCarthy,et al.  Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche , 2021, Cell.

[9]  H. Tang,et al.  Identification of Five Cytotoxicity-Related Genes Involved in the Progression of Triple-Negative Breast Cancer , 2022, Frontiers in Genetics.

[10]  Sharon Koorse Germans,et al.  The Role of Breast Cancer Stem Cells in Chemoresistance and Metastasis in Triple-Negative Breast Cancer , 2021, Cancers.

[11]  L. Gianni,et al.  Treatment landscape of triple-negative breast cancer — expanded options, evolving needs , 2021, Nature Reviews Clinical Oncology.

[12]  Nadezhda T. Doncheva,et al.  Correction to ‘The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets’ , 2021, Nucleic acids research.

[13]  A. Lánczky,et al.  Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation , 2021, Journal of medical Internet research.

[14]  J. Lathia,et al.  Cancer stem cell–immune cell crosstalk in tumour progression , 2021, Nature Reviews Cancer.

[15]  J. Gao,et al.  CDK1 promotes the stemness of lung cancer cells through interacting with Sox2 , 2021, Clinical and Translational Oncology.

[16]  T. Ho,et al.  ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor–activated cancer , 2021, Proceedings of the National Academy of Sciences.

[17]  B. Peethambaran,et al.  Regulation of cancer stem cells in triple negative breast cancer , 2021, Cancer drug resistance.

[18]  R. DePinho,et al.  Cancer Stemness Meets Immunity: From Mechanism to Therapy , 2021, Cell reports.

[19]  Bin Xu,et al.  Identification of biomarkers, pathways and potential therapeutic target for docetaxel resistant prostate cancer , 2021, Bioengineered.

[20]  Xijin Ge iDEP Web Application for RNA-Seq Data Analysis. , 2021, Methods in molecular biology.

[21]  S. Chouaib,et al.  Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies , 2021, Frontiers in Immunology.

[22]  B. Győrffy,et al.  TNMplot.com: A Web Tool for the Comparison of Gene Expression in Normal, Tumor and Metastatic Tissues , 2020, bioRxiv.

[23]  Navid Nezafat,et al.  Identification of Potential Biomarkers in Hepatocellular Carcinoma: A Network-Based Approach , 2020, Informatics in Medicine Unlocked.

[24]  X. Wan,et al.  Hypoxia induces an endometrial cancer stem-like cell phenotype via HIF-dependent demethylation of SOX2 mRNA , 2020, Oncogenesis.

[25]  Ping Huang,et al.  Integrative stemness characteristics associated with prognosis and the immune microenvironment in esophageal cancer. , 2020, Pharmacological research.

[26]  K. Hu,et al.  Transcription factor NFYA promotes G1/S cell cycle transition and cell proliferation by transactivating cyclin D1 and CDK4 in clear cell renal cell carcinoma. , 2020, American journal of cancer research.

[27]  Haosheng Jin,et al.  CDK1, CCNB1, and CCNB2 are Prognostic Biomarkers and Correlated with Immune Infiltration in Hepatocellular Carcinoma , 2020, Medical science monitor : international medical journal of experimental and clinical research.

[28]  Xiaole Shirley Liu,et al.  TIMER2.0 for analysis of tumor-infiltrating immune cells , 2020, Nucleic Acids Res..

[29]  V. Gopalan,et al.  Plasticity of Cancer Stem Cell: Origin and Role in Disease Progression and Therapy Resistance , 2020, Stem Cell Reviews and Reports.

[30]  R. Mantovani,et al.  Overexpression and alternative splicing of NF-YA in breast cancer , 2019, Scientific Reports.

[31]  Joseph O Deasy,et al.  Robust and interpretable PAM50 reclassification exhibits survival advantage for myoepithelial and immune phenotypes , 2019, npj Breast Cancer.

[32]  Jan Baumbach,et al.  Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology , 2019, Bioinform..

[33]  Alireza Hadj Khodabakhshi,et al.  Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.

[34]  Jiong Deng,et al.  Iron-dependent CDK1 activity promotes lung carcinogenesis via activation of the GP130/STAT3 signaling pathway , 2019, Cell Death & Disease.

[35]  Lydia Y. Liu,et al.  Molecular landmarks of tumor hypoxia across cancer types , 2019, Nature Genetics.

[36]  J. Deasy,et al.  Robust and interpretable PAM50 reclassification exhibits survival advantage for myoepithelial and immune phenotypes , 2018, npj Breast Cancer.

[37]  Allen W. Zhang,et al.  Cancer stemness, intratumoral heterogeneity, and immune response across cancers , 2018, Proceedings of the National Academy of Sciences.

[38]  Eun Woo Son,et al.  iDEP: an integrated web application for differential expression and pathway analysis of RNA-Seq data , 2018, BMC Bioinformatics.

[39]  X. Liu,et al.  Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.

[40]  Zheng Zhang,et al.  Gene regulatory network construction identified NFYA as a diffuse subtype-specific prognostic factor in gastric cancer , 2018, International journal of oncology.

[41]  Liang-Chih Liu,et al.  EZH2 promotes migration and invasion of triple-negative breast cancer cells via regulating TIMP2-MMP-2/-9 pathway. , 2018, American journal of cancer research.

[42]  Jin-Ming Yang,et al.  Silencing of NAC1 Expression Induces Cancer Cells Oxidative Stress in Hypoxia and Potentiates the Therapeutic Activity of Elesclomol , 2017, Front. Pharmacol..

[43]  C. Lindskog,et al.  A pathology atlas of the human cancer transcriptome , 2017, Science.

[44]  Chad J. Creighton,et al.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses , 2017, Neoplasia.

[45]  Yuhchyau Chen,et al.  Cisplatin treatment increases stemness through upregulation of hypoxia‐inducible factors by interleukin‐6 in non‐small cell lung cancer , 2016, Cancer science.

[46]  S. Masood Breast Cancer Subtypes: Morphologic and Biologic Characterization , 2016, Women's health.

[47]  Ching-Seng Ang,et al.  FunRich: An open access standalone functional enrichment and interaction network analysis tool , 2015, Proteomics.

[48]  H. Lyng,et al.  The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer , 2014, British Journal of Cancer.

[49]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[50]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[51]  A. Harris,et al.  Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene , 2010, British Journal of Cancer.

[52]  Crispin J. Miller,et al.  Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene , 2010, British Journal of Cancer.

[53]  J. Russo,et al.  ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. , 2009, Biochimica et biophysica acta.

[54]  Sean R. Davis,et al.  GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor , 2007, Bioinform..

[55]  Crispin J. Miller,et al.  Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. , 2007, Cancer research.

[56]  I. Shih,et al.  A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival , 2006, Proceedings of the National Academy of Sciences.

[57]  P. Defossez,et al.  Born to bind: the BTB protein–protein interaction domain , 2006, BioEssays : news and reviews in molecular, cellular and developmental biology.

[58]  Seon-Young Kim,et al.  PAGE: Parametric Analysis of Gene Set Enrichment , 2005, BMC Bioinform..